Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells

American Journal of Tropical Medicine and Hygiene

Volumn 87, Issue 1, 2012, Pages 64-69

  Oga, Enoche F ^a   Sekine, Shuichi ^a   Shitara, Yoshihisa ^a   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIGOXIN; GLYCOPROTEIN P; QUINIDINE; RHODAMINE 123; SULFADOXINE; VERAPAMIL;

APICAL MEMBRANE; ARTICLE; BASAL CELL; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL;

ANTIMALARIALS; CACO-2 CELLS; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; RHODAMINE 123;

ARTESUNATE;

EID: 84863767857     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0817     Document Type: Article

References (32)

1. WHO, 2000. World Health Organization Expert Committee on Malaria. 20th Report, WHO, Geneva. Available at: http://www.rollbackmalaria.org/docs/ecr20. pdf. Accessed April 28, 2011.
2. Breman JG, Alilio MS, Mills A, 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 1-15. (Pubitemid 39127486)
3. Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW, 2005. Urbanization, malaria transmission and disease burden in Africa. Nat Rev Microbiol 3: 81-90. (Pubitemid 40028471)
4. Brentlinger P, Behrens C, Mice M, 2006. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis 6: 100-111. (Pubitemid 43138908)
5. Fehintola FA, Akinyinka OO, Adewole IF, Maponga CC, Ma Q, Morse GD, 2011. Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab 12: 51-56.
6. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
7. Giacomini K, Sugiyama Y, 2005. Membrane transporters and drug response. Brunton LL, Lazo JS, Parker KL, eds. Goodman &Gilman's: The Pharmacological Basis of Therapeutics. NewYork: McGraw-Hill, 41-70.
8. Tanigawara Y, 2000. Role of P-glycoprotein in drug disposition. Ther Drug Monit 22: 137-140. (Pubitemid 30083115)
9. Kato M, Shitara Y, Kitajima M, Tachibana T, Ishigai M, Horie T, Sugiyama Y, 2010. Extrapolation of in vitro metabolic and P-glycoprotein-mediated transport data to in vivo by modeling and simulation. Pang KS, Rodrigues AD, Peter R, eds. Enzyme-and Transporter-based Drug-Drug interactions, Progress and Future Challenges. New York: Springer, 299-315.
10. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y, 2009. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39: 430-443.
11. Rostami-Hodjegan A, Tucker G, 2004. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today Technol 1: 441-448. (Pubitemid 40186348)
12. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, Moriwaki T, 2011. Establishment of in vitro Pglycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100: 4013-4023.
13. Cavet ME, West M, Simmons NL, 1996. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118: 1389-1396. (Pubitemid 26248789)
14. Lin JH, 2007. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3: 81-92. (Pubitemid 47307456)
15. Horn J, Hansten P, 2004. Drug interactions with digoxin: the role of P-glycoprotein. Pharm Times October, 45-46.
16. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T, 1998. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358: 289-294. (Pubitemid 28498189)
17. Artursson P, Palm K, Luthman K, 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27-43.
18. Dressman JB, Amidon GL, Reppas C, Shah VP, 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15: 11-22. (Pubitemid 28080861)
19. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL, 2006. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 29: 70-81. (Pubitemid 44294861)
20. Reungpatthanaphong P, Mankhetkorn S, 2002. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25: 1555-1561. (Pubitemid 39663669)
21. Zhang L, Zhang YD, Zhao P, Huang SM, 2009. Predicting drug-drug interactions: an FDA perspective. AAPS J 11: 300-306.
22. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR, 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289-294. (Pubitemid 28067324)
23. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J, 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73: 1573-1581. (Pubitemid 46527547)
24. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y, 2010. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 48: 407-414.
25. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM, 2006. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother 50: 3504-3506. (Pubitemid 44527539)
26. Pham YT, Regina A, Farinotti R, Couraud P, Wainer IW, Roux F, Gimenez F, 2000. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 1524: 212-219.
27. Qi J, Wang S, Liu G, Peng H, Wang J, Zhu Z, Yang C, 2004. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun 319: 1124-1131. (Pubitemid 38759528)
28. WHO, 2010. Guidelines for the Treatment of Malaria. Second edition. Geneva: World Health Organization Press, 194.
29. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, Guerin PJ, Laufer MK, Naidoo I, Nosten F, Olliaro P, Plowe CV, Ringwald P, Sibley CH, Stepniewska K, White NJ, 2007. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J 6: 119.
30. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE, 2007. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J 6: 120.
31. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ, 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71: 179-186. (Pubitemid 39121321)
32. White NJ, 2004. Antimalarial drug resistance. J Clin Invest 113: 1084-1092. (Pubitemid 38544090)